NCI

U.K.’s MRC invests over $17M in stratified medicine research

Thursday, December 13, 2012 08:00 AM

The U.K.’s Medical Research Council (MRC) plans to invest $17.1 million in three major new collaborations that will advance the emerging field of stratified medicine—investigating why different patients with the same diagnosis respond differently to treatments.

More... »

Factor Bioscience awarded two NIH grants for Alzheimer's research

Monday, November 19, 2012 11:12 AM

The National Institutes of Health, through the National Center for Advancing Translational Sciences, has awarded Factor Bioscience, a developer of cell-based therapeutics and research tools, two Small Business Innovation Research (SBIR) grants to accelerate the development of new treatments for Alzheimer's disease.

More... »

$11.3M awarded to researchers through MRC-AZ compound collaboration

Thursday, November 1, 2012 09:56 AM

The Medical Research Council (MRC) has awarded $11.3 million of funding for 15 research projects awarded through its collaboration with global biopharmaceutical company AstraZeneca, which gave academic researchers unprecedented access to 22 chemical compounds.

More... »

Principia Biopharma secures $12.5M second tranche in Series A financing

Tuesday, October 30, 2012 10:51 AM

Principia Biopharma, a South San Francisco-based privately held biopharmaceutical company focused on advancing best-in-class medicines in immunology, autoimmune diseases, and oncology, has successfully met its milestone obligations and received its second tranche of funding totaling $12.5 million.

More... »

Leading researchers outline principles for conduct of comparative effectiveness research

Wednesday, September 12, 2012 11:51 AM

A new set of principles developed by a group of leading researchers could help to ensure more consistency in how comparative effectiveness research (CER) is planned and conducted. These guiding principles were published in the September issue of The Journal of Comparative Effectiveness Research.

More... »

Transgenomic awarded NIH STTR grant for pancreatic cancer research

Thursday, August 23, 2012 11:15 AM

Transgenomic,an Omaha, Neb.-based global biotechnology company focused on personalized medicine, has been awarded a $100,000 Small Business Technology Transfer Program (STTR) phase I grant by the National Institutes of Health’s National Center For Advancing Translational Sciences.

More... »

OncoSec establishes UCSF clinical site for phase II Merkel cell carcinoma trial

Wednesday, July 11, 2012 10:22 AM

OncoSec Medical, a biopharmaceutical company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, has established the University of California San Francisco (UCSF) as the second enrolling site for its phase II Merkel cell carcinoma study (OMS-I110).

More... »

IPC leads effort to clarify the genetic architecture of psoriasis

Wednesday, June 20, 2012 03:47 PM

The International Psoriasis Council (IPC) announced the publication of a report in the British Journal of Dermatology’s June edition that summarizes the IPC’s efforts to establish collaboration among leading geneticists and dermatologists to advance the understanding of the genetic basis of psoriasis.

More... »

NCIC CTG to sponsor, conduct colorectal cancer study for Oncolytics

Friday, May 4, 2012 04:36 PM

Calgary, Alberta-based Oncolytics Biotech has chosen NCIC Clinical Trials Group at Queen's University in Kingston, Ontario, to sponsor and conduct a randomized phase II study of Reolysin in patients with advanced or metastatic colorectal cancer.

More... »

NIH launches collaborative program to spur therapeutic development

Friday, May 4, 2012 08:02 AM

The National Institutes of Health (NIH) has unveiled a collaborative program, Discovering New Therapeutic Uses for Existing Molecules, that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients.

More... »